Novo Holdings participates in series B round at Belgian cancer firm

Biotech company Precirix raises EUR 80m from a consortium of investors, which included Novo Holdings.

Photo: Novo Holdings / PR

Belgian biotech firm Precirix has finished a series B financing round raising EUR 80m, a press release reports.

The round was led by new investors Inkef Capital, Jeito and Forbion, which join the company’s ownership circle that already counts Novo Holdings, Gimv, Healthcap, Pontifax Venture Capital, V-Bio Ventures and Biomed Partners. The existing owners participated in the fundraising round alongside the company’s seed investors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs